Please login to the form below
OAB
This page shows the latest OAB news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB patients with benign prostatic hyperplasia, plus a third trial in patients with
Latest news
-
Germany’s IQWiG denies Astellas’ incontinence drug
OAB). This review will be taken into consideration by the Federal Joint Committee (GBA), which will then recommend on whether the drug should be reimbursed on Germany's healthcare system. ... The decision is in contrast to the positive guidance from the
-
Astellas uses animated bladder in campaign
The campaign is for overactive bladder (OAB) drug Myrbetriq shows an untreated bladder character constantly interrupting a woman as she goes about her daily activities (see video above or on YouTube). ... The new campaign is aimed at women aged 45-69
-
Astellas gets first OK for prostate drug Vesomni
Urology is a core product franchise for Astellas, with its standalone Harnal (tamsulosin) product for BPH and overactive bladder (OAB) therapy Vesicare (solifenacin) bringing in sales of 67bn yen and 87bn ... The company has already added to its OAB
-
NICE recommends Astellas' Betmiga for overactive bladder
Final draft guidance recommends Vesicare successor
-
Allergan gets US approval for Botox in overactive bladder
OAB caused by neuronal damage, for example as a result of spinal cord injury or multiple sclerosis. ... OAB is a condition in which the bladder squeezes too often or squeezes without warning, leading to urinary incontinence, sudden urgent need to urinate
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new ... class of OAB treatments to emerge in over 30 years, the
-
Interview: Kay Drake and Naoki Okamura, Astellas
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Astellas strengthens US and Canadian leadership team
As Sabus leaves from the US, Astellas has promoted Lynn Fenicchia Gerber (pictured left) to US vice president, primary care, where she will lead sales efforts for the OAB, anti-fungal,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
emotive project Decisions in Time wins gold for the Digital solution for congress/symposium at the 2014 PM Digital Media Awards
Other emotive projects OAB Health Economics won silver in the Craft Award – Mobile and Diabetes Voyager won bronze in the Innovation Award – Pushing Boundaries.
-
Award-winning emotive project, Decisions in Time, nominated as a finalist in yet more pharmaceutical awards
Along with emotive projects like Diabetes Voyager and OAB Health Economics and Neil Kumar being nominated for Account Manager of the Year, emotive is a finalist for a total of six
-
emotive client Adam Boucher of Novo Nordisk announced as a finalist for Digital Pioneer at the 2014 PM Digital Awards
OAB Health Economics app has been nominated in the Craft Award – Mobile category. -
-
Neil Kumar announced as a finalist for Account Manager of the Year at the PM Society Digital Media Awards 2014
OAB Health Economics app.
-
emotive is thrilled to be a sponsor of the PM Society’s Digital Media Awards 2014
Craft Award – Mobile for OAB Health Economics.
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
Featured jobs
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Brexit rebels win vote on European Medicines Agency alignment
- AstraZeneca joins Merck in Brexit stockpiling effort
- NHS England to Vertex: come clean on Orkambi offer
- Moving annual total (MAT)
- Vyriad inks immunotherapy alliance with Merck/Pfizer
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
